Artal Group S.A. Syros Pharmaceuticals, Inc. Transaction History

Artal Group S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	BUY	$0.69 - $1.21 $345,000 - $605,000	500,000 Added 14.29%	4,000,000 $3.85 Million
Q1 2022 May 12, 2022	BUY	$1.02 - $3.8 $510,000 - $1.9 Million	500,000 Added 16.67%	3,500,000 $4.17 Million
Q4 2021 Feb 11, 2022	BUY	$3.26 - $4.66 $3.26 Million - $4.66 Million	1,000,000 Added 50.0%	3,000,000 $9.78 Million
Q3 2021 Nov 12, 2021	BUY	$4.08 - $5.66 $1.22 Million - $1.7 Million	300,000 Added 17.65%	2,000,000 $8.94 Million
Q2 2021 Aug 13, 2021	BUY	$5.01 - $7.48 $3.38 Million - $5.05 Million	675,000 Added 65.85%	1,700,000 $9.27 Million
Q1 2021 May 14, 2021	BUY	$7.19 - $14.95 $1.98 Million - $4.11 Million	275,000 Added 36.67%	1,025,000 $7.67 Million
Q4 2020 Feb 11, 2021	BUY	$6.66 - $14.66 $1.89 Million - $4.17 Million	284,500 Added 61.12%	750,000 $8.14 Million
Q3 2020 Nov 13, 2020	SELL	$8.69 - $14.47 $212,905 - $354,515	-24,500 Reduced 5.0%	465,500 $4.12 Million
Q2 2020 Aug 14, 2020	SELL	$5.21 - $11.03 $84,078 - $178,002	-16,138 Reduced 3.19%	490,000 $5.22 Million
Q1 2020 May 14, 2020	BUY	$4.46 - $9.2 $2.26 Million - $4.66 Million	506,138 New	506,138 $3 Million

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.